V1 receptor Inhibitors
3 drugsAbout V1 receptor
The V1 receptor, also known as vasopressin receptor 1A (AVPR1A), is a G protein-coupled receptor that binds vasopressin, regulating blood pressure and fluid balance. It influences social behaviors through downstream signaling.
Genetic evidence offers moderate support for AVPR1A as a therapeutic target, with a max score of 0.31. Associations include frozen shoulder and glomerulonephritis (score 0.31).
Three FDA-approved small molecule drugs target the V1 receptor, including VASOPRESSIN. These drugs are marketed by Dr. Reddy's, Baxter, and GLAND.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Hemorrhage with only 1 trials.
V1 receptor Genetic Evidence Moderate
Genetic evidence shows moderate support for AVPR1A, with a max score of 0.31.
Further research is needed to validate AVPR1A as a drug target, given the moderate genetic support.
Evidence Across Diseases
5 totalGWAS and other genetic studies link AVPR1A to 5 diseases.
🔗 Colocalization Evidence 18 strong
max H4: 0.99eQTL/pQTL signals for AVPR1A colocalize with these GWAS traits, providing causal evidence that gene expression changes drive disease risk.
Understanding these scores
Association Score (0-1): Combines all evidence types (genetic, literature, drugs, animal models). Higher = more evidence linking target to disease. This is a ranking heuristic, not a confidence score.
L2G Score: Open Targets uses a machine learning model (Locus-to-Gene) to predict which gene is causal at each GWAS locus. L2G=0.5 means ~50% probability of being the causal gene. Only associations with L2G > 0.05 are included.
Odds Ratio (OR): From gene burden studies (UK Biobank, AstraZeneca PheWAS). Measures how loss-of-function variants affect disease risk. OR<1 = protective (inhibiting target may help), OR>1 = risk (losing function causes disease).
Beta (β): Effect size for continuous traits. β<0 = protective, β>0 = risk.
Clinical Translation (~1.8x): Based on Nelson et al. 2015: drug targets with genetic evidence have ~2x higher success rates in clinical trials. We estimate: Strong support (score ≥0.7) → ~1.8x, Moderate (0.3-0.7) → ~1.3x, Weak → baseline.
Colocalization (H4): Tests whether a GWAS signal and an eQTL/pQTL signal share the same causal variant. H4 is the posterior probability that both traits are associated AND share a causal variant. H4 > 0.8 = strong evidence that gene expression/protein levels drive disease risk. This links genetic variation → gene expression → disease, supporting the target-disease connection.
Top V1 receptor Drugs
The competitive landscape includes Dr. Reddy's, Baxter, and GLAND, each with approved drugs.
The presence of only 3 companies suggests a relatively unconcentrated market with potential entry opportunities.
V1 receptor Drug Modality Landscape
Modalities
Routes of Administration
V1 receptor is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
V1 receptor Clinical Trials 140 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 11 | 3 | 3 | 79% |
| Phase 2 | 42 | 25 | 10 | 7 | 71% |
| Phase 3 | 30 | 17 | 3 | 10 | 85% |
| Phase 4 | 51 | 28 | 7 | 14 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
V1 receptor Drug Approval Timeline (2023 - 2024)
The first drug was approved in 2020, with the most recent approval in 2024.
The recent approval suggests continued interest in the target, but further approvals may saturate the market.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 117 clinical trials targeting V1 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities